PremiumRatingsAvidity Biosciences Positioned for Market Leadership with Promising DM1 Treatment in Phase 3 Trial Avidity Biosciences initiated with an Outperform at Wolfe Research Avidity Biosciences initiated with an Outperform at Wolfe Research PremiumThe FlyAvidity Biosciences price target raised to $75 from $70 at Citi Avidity Biosciences price target raised to $59 from $57 at Barclays Avidity data strengthens accelerated approval case, says H.C. Wainwright PremiumCompany AnnouncementsAvidity Biosciences Launches Global Phase 3 Study Avidity Biosciences announces results from Phase 1/2 FORTITUDE program Avidity announces accelerated approval regulatory pathway for Del-Brax 
